GLUCAGON Drug Patent Profile
✉ Email this page to a colleague
When do Glucagon patents expire, and when can generic versions of Glucagon launch?
Glucagon is a drug marketed by Amphastar Pharms Inc, Lilly, and Fresenius Kabi Usa. and is included in four NDAs.
The generic ingredient in GLUCAGON is glucagon hydrochloride. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
Summary for GLUCAGON
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 27 |
| Clinical Trials: | 809 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for GLUCAGON |
| What excipients (inactive ingredients) are in GLUCAGON? | GLUCAGON excipients list |
| DailyMed Link: | GLUCAGON at DailyMed |
Recent Clinical Trials for GLUCAGON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Colorado, Denver | Phase 3 |
| Neurobiology Research Unit | Phase 2 |
| Amir Moheet | Phase 2/Phase 3 |
Pharmacology for GLUCAGON
Medical Subject Heading (MeSH) Categories for GLUCAGON
Anatomical Therapeutic Chemical (ATC) Classes for GLUCAGON
US Patents and Regulatory Information for GLUCAGON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharms Inc | GLUCAGON | glucagon | INJECTABLE;INJECTION | 208086-001 | Dec 28, 2020 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for GLUCAGON
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Tetris Pharma B.V | Ogluo | glucagon | EMEA/H/C/005391 Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. |
Authorised | no | no | no | 2021-02-11 | |
| Eli Lilly Nederland B.V. | Baqsimi | glucagon | EMEA/H/C/003848 Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. |
Authorised | no | no | no | 2019-12-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
